vimarsana.com

Pirtobrutinib News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr Brown on the Potential for Pirtobrutinib to Address Treatment Discontinuation in CLL

Jennifer R. Brown, MD, PhD, discusses how pirtobrutinib may address BTK inhibitor discontinuation in chronic lymphocytic leukemia.

Jenniferr brownChronic lymphocytic leukemia centerDana farber cancer instituteHarvard medical schoolMargaret collette professorHematologic oncologyAsh annual meetingChronic lymphocytic leukemiaJennifer brown

Bispecific Antibodies and Noncovalent BTK Inhibitors Expand Horizons in DLBCL and MCL

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

United statesUniversity of california irvineCatherinec coombsNiravn shahSwetha kambhampatiDepartment of medicineCollege of wisconsinDivision of hematologySchool of medicineCalifornia irvineOnclive institutional perspectivesMedical collegeMantle cell lymphomaLargeb cell lymphomaBispecific antibodies

Current Treatment Options in Third-line MCL

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

Recent updatesFollicular lymphomaMantle cell lymphomaTreatment optionsThird lineThird line mclCart cellsZuma 2Brexu celZuma 2 trialHigh risk patientsOverall survivalLiso celCart cell therapy

Sequencing Therapies in the Third-Line and Beyond Setting for MCL

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

Recent updatesFollicular lymphomaMantle cell lymphomaBeyond settingSequencing therapyBrexu celBtk inhibitorCart cell therapyLiso cel

Expert Perspectives on Emerging Data Surrounding BTK Inhibitor Resistance in CLL

Faculty offer expert insights into emerging data on BTK inhibitor resistance in CLL, referencing earlier findings that indicate the potential existence of mutations before BTK inhibitor exposure and the process of clonal selection.

Chaitras ujjaniRichard furmanNews networkChronic lymphocytic leukemiaContinuous btki therapyFixed duration therapyTumor lysis monitoringElevate tnMash 2023Elevate rrTreatment naïve cllNewly diagnosed cllRelapsed cllRefractory cllReal world dataTreatment resistance

vimarsana © 2020. All Rights Reserved.